|
Board members and committee assignments are listed in the table below.
|
 = Chairman of the Board
 = Chair  = Member
 = Independent Director
| |
Audit
|
Compensation
|
Nominating
|
|
Eric L. Sorkin
|
|
|
|
|
Chairman and Chief Executive Officer Mr. Sorkin has 25 years of making strategic investments and business development. He has been
affiliated with Immtech since 1998, when he became an investor. In 2000, Mr. Sorkin became a director
for the Company, and more recently was appointed Chairman of the Board and CEO. Mr. Sorkin began
his career on Wall Street in 1982 working at Dean Witter, which is now a subsidiary of Morgan Stanley,
and from an entry-level position, he was promoted to Managing Director within six years. He was among
the core group of professionals at the firm, which developed the firm's investment portfolio with assets
of over USD $3 billion. Mr. Sorkin was responsible for investment selection, negotiations, transaction and
financial structuring, debt placement, and asset management. Mr. Sorkin was Officer of over 20 public
investment partnerships with investment funds totaling over USD $1 billion. In 1993, Mr. Sorkin created
his own investment firm and began making private equity investments in the U.S. and in China. Mr. Sorkin
graduated from Yale University with a B.A. in Economics.
Holdings: 75,453 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Nov 14, 2007 |
Option Execute |
10,972 |
2.55 - 6.47 |
| Apr 15, 2007 |
Acquisition (Non Open Market) |
2,117 |
6.57 |
| Feb 14, 2007 |
Option Execute |
4,000 |
6.00 |
| Oct 15, 2006 |
Acquisition (Non Open Market) |
2,637 |
5.30 |
| Apr 15, 2006 |
Acquisition (Non Open Market) |
1,169 |
7.87 |
| Nov 14, 2005 |
Option Execute |
10,000 |
6.47 |
| Nov 10, 2005 |
Option Execute |
5,000 |
6.47 |
| Aug 29, 2005 |
Disposition (Non Open Market) |
200 |
n/a |
| Aug 29, 2005 |
Option Execute |
6,028 |
2.55 |
|
|
Cecilia Chan
|
|
|
|
|
Vice Chairman Ms. Chan has 22 years of experience in making strategic investments and business development.
She began working on Immtech's growth strategy in 1998 and spearheaded Immtech's initial public
offering in April 1999. Ms. Chan is responsible for strategic development, creating joint ventures,
fundraising, and directing the Company's uses of capital resources as the firm advances through
its various growth stages and achievements. Prior to joining Immtech, Ms. Chan was a Vice President
at Dean Witter until 1993. During her eight years at that firm Ms. Chan completed over $500 million
in investments and was Officer of public partnerships with assets of over $800 million. Since 1993,
Ms. Chan has developed and funded investments in the U.S. and in China. She graduated from
New York University with a Bachelor of Science degree in International Business.
| Holdings: 392,270 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Sep 25, 2007 |
Option Execute |
2,312 |
6.13 |
| Apr 15, 2007 |
Acquisition (Non Open Market) |
410 |
6.57 |
| Feb 2, 2007 |
Disposition (Non Open Market) |
3,583 |
n/a |
| Oct 15, 2006 |
Acquisition (Non Open Market) |
510 |
5.30 |
| Apr 15, 2006 |
Acquisition (Non Open Market) |
342 |
7.87 |
| Nov 14, 2005 |
Option Execute |
8,000 |
2.55 |
| Sep 26, 2005 |
Option Execute |
10,000 |
2.55 |
| May 12, 2005 |
Option Execute |
11,800 |
2.55 - 6.47 |
|
|
David Fleet
|
|
|
|
|
Principal, David Fleet Pharmaceutical Industry Consultancy Services Non-Executive Director, OnMedica Group Ltd.
Director, IatRx Pharma Ltd.
Mr. Fleet has over 35 years of experience in the international pharmaceutical industry with proven sucess
in business development, sales and marketing, manufacturing and technical roles in the U.S., Japan, Europe,
and the Middle East. He has consulted for King Pharmaceuticals, Inc., Aspen Pharmacare Ltd., Living Cell
Technologies Ltd., and Trigen AG. Mr. Fleet has also consulted for Vestar Capital Partners, MPM Capital,
Bear Stearns, and Warburg Pincus, and he is a Non-Executive Director of OnMedica Group Ltd., a leading
European physician internet website.
From 1997 to 2002, Mr. Fleet was SVP of Global Business Development for Innovex Ltd. From 1993 to 1996,
he was a founding shareholder of Innovex, responsible for global business development and establishment
of principal subsidiaries in Germany, the U.S., and Japan. Mr. Fleet also spent 10 years at Schering-Plough,
where he was responsible for various operations, including development and growth of the ethical and OTC
products business as Area Director for the Middle East and Africa. He was also manager of Schering-Plough's
third largest pharmaceutical plant in Europe with responsibility for manufacturing operations for a full
range of pharmaceutical products.
Mr. Fleet began his career at Ward Blenkinsop & Co., Ltd., a division of Boehringer Ingelheim, and was
also with Major & Company Manufacturing, where he had managerial responsibilities over multiple
pharmaceutical plants with large local and expatriate staff in West Africa. In addition to Mr. Fleet's
global business development and managerial skills, he has extensive experience in negotiating with
government agencies, including the Department of Health from the United Kingdom, and European, Middle
Eastern, and African Ministries of Health.
|
|
Judy Lau
|
|
|
|
|
Chairperson, Convergent Business Group, Hong Kong, PRC Ms. Lau has served as Director since October 31, 2003. Since July 2002, Ms. Lau has served as the Chairperson of Convergent Business Group, a Hong Kong-based investment advisory firm with investments focused in high technology, life sciences, healthcare and environmental engineering projects in the greater China region. From May of 2001 to July of 2002, Ms. Lau served as General Manager of China Overseas Venture Capital Co. Ltd., a venture capital firm. From October of 2000 to April of 2001, Ms. Lau served as Chief Executive Officer of the Good Fellow Group, a Chinese investment firm; and from March of 1999 to September of 2000, Ms. Lau was the Managing Director of America Online HK, an Internet Service Provider and Hong Kong affiliate of Time Warner, Inc. From April of 1998 to February of 1999, Ms. Lau worked as a consultant to Pacific Century Group. Ms. Lau has served in the position of Director of Immtech Hong Kong Ltd. since June, 2003. Ms. Lau was named in 2000, one of the thirty-six most influential Business Women of Hong Kong by Capital Magazine and is a Fellow of the Hong Kong Association for the Advancement of Science and Technology.
|
|
Levi Hong Kaye Lee, M.D.
|
|
|
|
|
Queen Mary Hospital, Hong Kong, PRC Dr. Lee has served as Director since October 31, 2003. Dr. Lee has been in private medical practice, specializing in pediatrics, since 1971. His practice is located in Hong Kong. Dr. Lee received a B.A. in Biochemistry from the University of California, Berkeley, in 1962, and received his M.D. from the University of California, San Francisco, in 1966. Dr. Lee has served in the position of Director of Immtech Hong Kong Ltd. since June, 2003. He was appointed a Diplomat of the American Board of Pediatrics in 1971.
| Holdings: 11,900 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Dec 28, 2007 |
Sell |
9,000 |
2.15 |
| Dec 28, 2007 |
Sell |
9,078 |
2.15 |
| Aug 3, 2006 |
Buy |
200 |
5.00 |
| Nov 11, 2005 |
Buy |
1,000 |
7.39 |
|
|
Donald F. Sinex
|
|
|
|
|
Board Director, Devonwood, Inc. Donald F. Sinex has been making and managing investments for over 25 years, and is the Founder and Managing Partner of Devonwood Investors, LLC ("Devonwood"). Prior to founding Devonwood, Mr. Sinex was an Executive Vice President and Managing Director of JMB Realty Corporation, one of the largest commercial real estate companies in the U.S.. At JMB, he was in charge of real estate acquisitions and investments in New York City, Washington and Boston. He acquired more than $6.5 billion of assets during his tenure. Mr. Sinex retired from JMB in 1997 and founded Devonwood, a private equity firm that originates investments in high growth businesses. Mr. Sinex has also been an active and successful independent investor for decades. He received his BA (highest honors) from the University of Delaware in 1972; JD (highest honors) from the University of Miami School of Law in 1976, where he also served as an editor and member of the law review, and an MBA from the Harvard Business School.
| Holdings: 36,636 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Oct 16, 2006 |
Statement of Ownership |
0 |
n/a |
|
Stock transaction information provided by EDGAR Online. Immtech Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
Contact the Board
You can contact Immtech Pharmaceuticals, Inc.'s Board Members to provide comments, to report concerns, or to ask a question, at the following address.
Corporate Secretary
Immtech Pharmaceuticals, Inc.
150 Fairway Dr., Ste. 150
Vernon Hills, IL 60061
United States
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Immtech Pharmaceuticals, Inc. board members have requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
- Product complaints
- Product inquiries
- New product suggestions
- Resumes and other forms of job inquiries
- Surveys
- Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
You may also
communicate online with our board members as a group.
|
